National Cancer Institute gets GOBIOM license from GVK Biosciences
Singapore: GVK Biosciences, Asia's leading contract research organization (CRO) has licensed its popular clinical biomarker database (GOBIOM) to the prestigious Division of Cancer Prevention (DCP), National Cancer Institute (NCI).
The GOBIOM (GVK BIO Online Biomarker Database) is a comprehensive collection of all clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 15,500 biomarkers comprising of biochemical, genomic, imaging, metabolite, cellular and physiological markers with multiple data points covering experimental, analytical, clinical, preclinical and statistical data with their qualifications under different medical interventions.
GOBIOM covers over 100 different ethnicities, provides extensive information on approved assay methodologies and companion diagnostics, and is a powerful tool for researchers and clinicians worldwide. Biomarker research is growing exponentially in the area of oncology. The GVK Database has over 6,000 clinically evaluated markers in oncology and growing.
"GVK BIO is pleased that the DCP chose the GVK BIO biomarker database for its research efforts. It is a clear testimony to the quality, content and utility of the database. We look forward to working with DCP. The coverage in oncology will enable researchers at the DCP to acceler their discovery efforts", said Mr Sreeni Devidas, VP, sales and marketing, informatics, GVK Biosciences.
